BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol 2022;15:110. [PMID: 35978372 DOI: 10.1186/s13045-022-01328-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Xiao W, Yu Y, Jiang Y, Xiao Z, Huang D, Zhong T, Li J, Xiang X, He Y, Li Z. Colorectal cancer-derived extracellular vesicles containing HSP70 enhance macrophage phagocytosis by up-regulating MARCO expression. Exp Cell Res 2023;:113565. [PMID: 36958650 DOI: 10.1016/j.yexcr.2023.113565] [Reference Citation Analysis]
2 Koedijk JB, van der Werf I, Vermeulen MA, Perzolli A, Fiocco M, de Groot-kruseman HA, Moeniralam R, Nierkens S, Belderbos ME, Zwaan CM, Heidenreich O. Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia.. [DOI: 10.1101/2023.03.03.23286485] [Reference Citation Analysis]
3 Yu J, Li S, Chen D, Liu D, Guo H, Yang C, Zhang W, Zhang L, Zhao G, Tu X, Peng L, Liu S, Bai X, Song Y, Jiang Z, Zhang R, Tian W. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 2023;37:695-8. [PMID: 36575242 DOI: 10.1038/s41375-022-01805-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark Res 2023;11:15. [PMID: 36726125 DOI: 10.1186/s40364-023-00456-x] [Reference Citation Analysis]
5 Samanas NB, Murphy RC, Miralda I, Hallstrand TS, Piliponsky AM. Neutrophilic asthma at an inhibitory checkpoint: A PD-1-targeted approach. J Allergy Clin Immunol 2023;151:420-2. [PMID: 36463980 DOI: 10.1016/j.jaci.2022.11.014] [Reference Citation Analysis]
6 Liu M, Liu L, Song Y, Li W, Xu L. Targeting macrophages: a novel treatment strategy in solid tumors. J Transl Med 2022;20:586. [PMID: 36510315 DOI: 10.1186/s12967-022-03813-w] [Reference Citation Analysis]
7 Sun H, Li Y, Zhang P, Xing H, Zhao S, Song Y, Wan D, Yu J. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomark Res 2022;10:89. [PMID: 36476317 DOI: 10.1186/s40364-022-00436-7] [Reference Citation Analysis]
8 Yu J, Li S, Chen D, Liu D, Guo H, Yang C, Zhang W, Zhang L, Zhao G, Tu X, Peng L, Liu S, Bai X, Song Y, Jiang Z, Zhang R, Tian W. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal. J Hematol Oncol 2022;15:167. [DOI: 10.1186/s13045-022-01385-2] [Reference Citation Analysis]
9 Nogami A, Sasaki K. Therapeutic Advances in Immunotherapies for Hematological Malignancies. IJMS 2022;23:11526. [DOI: 10.3390/ijms231911526] [Reference Citation Analysis]